Integrating Network Pharmacology, Molecular Docking, and Experimental Validation to Investigate the Mechanism of (-)-Guaiol Against Lung Adenocarcinoma

Yaoying Zeng; Yanbin Pan; Bo Zhang; Yingbin Luo; Jianhui Tian; Yuli Wang; Xudong Ju; Jianchun Wu; Yan Li

doi:10.12659/MSM.937131

25 July 2022 : Database Analysis

Integrating Network Pharmacology, Molecular Docking, and Experimental Validation to Investigate the Mechanism of (-)-Guaiol Against Lung Adenocarcinoma

Yaoying Zeng^1E, Yanbin Pan^1B, Bo Zhang^1C, Yingbin Luo^1D, Jianhui Tian^1AF, Yuli Wang^1CD, Xudong Ju^2BF, Jianchun Wu^1A*, Yan Li^1A

DOI: 10.12659/MSM.937131

Med Sci Monit 2022; 28:e937131

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 10 (−)-Guaiol regulates the expression of related proteins in PI3K/Akt Signaling Pathway. Western blot analysis was used to detect the protein expression of PI3K, p-PI3K, Akt, and p-Akt in A549 treated with or without (−)-Guaiol (75 μM) or LY294002 (15 μM). The relative protein levels from 3 independent experiments were statistically analyzed using ANOVA in the quantitative analysis. * P<0.05, ** P<0.01, *** P<0.001 vs control. ## P<0.01, ### P<0.001 vs LY294002.

Back to the Article

Integrating Network Pharmacology, Molecular Docking, and Experimental Validation to Investigate the Mechanism of (-)-Guaiol Against Lung Adenocarcinoma

Your Privacy